TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: AUCT,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of sonar guided true cut needle biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to plasma viral rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease of aortic valve calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Injection Site and Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: MELISA test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in allograft kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sustained Virologic Response (SVR) at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Body Image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUClast of digoxin and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of digoxin and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of digoxin and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of tumor burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Foot infection and recurrence of foot ulcer
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Wild Type-4 Febrile Adenovirus Acute Respiratory Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Showing ADV-7 Seroconversion at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time From Randomization to Any Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional communicative ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity of the oncotectTM HPV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p-cresyl sulfate serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve of salivary fluoride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of tooth brushing at home
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Child oral health according to standardized measures from visual exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Severity Rating on Anxiety Diagnostic Interview Schedule for Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum markers of extracellular matrix proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of solicited AEs (local and systemic reactogenicity events)
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titer (GMT) of the serum anti-hMPV and anti-PIV3 neutralizing antibodies
Endpoint domain: Physiological/clinical
Primary endpoint: Proportion of subjects with a ≥ 4-fold increase in serum anti-hMPV and anti-PIV3 neutralizing antibody titer from baseline to post-vaccination
Endpoint domain: Physiological/clinical
Primary endpoint: Mean cross-sectional area of the PTN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-inferiority of iontophoretic CXL compared to standard CXL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glycated Haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: occurrence or frequency of recurrences of laryngeal papillomatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Menstrual Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Days of Alcohol or Substance Misuse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Use of Decision Support System by Nurses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Amount of Second Hand Smoke Exposure in Children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Standard deviation from the centre of the road
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of off-road events per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual rate of moderate or severe COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Event Free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Infectivity of the administration regimens
Endpoint domain: Adverse events/effects
Primary endpoint: PET/CT Measurements of Myocardial FA Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma PK parameters of R406
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hour Post Load Plasma Glucose (2-h PG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycated Hemoglobin A1c (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Interleukin-1beta Level in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute Change in Interleukin-6 Level in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Tumor Necrosis Factor-alpha Level in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time from collapse to achieving desired range of cooling (32.0 to 34.0°C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from deployment of the ThermoSuit™ to core temperature < 34.0°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time during the first 24 hours after cooling is initiated that the core temperature is between 32.0 and 34.0°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-averaged summed pain intensity difference 15 min after STA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unexpected Intensive Care Unit Admissions
Endpoint domain: Adverse events/effects
Primary endpoint: Rapid Response Team Activations
Endpoint domain: Adverse events/effects
Primary endpoint: Metagenomic profile change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of Rosuvastatin (AUC and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of Simvastatin (AUC and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Total Score of Dentine Hyersensitivity Experience Questionnaire (DHEQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viscosity of endometrial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Days a Participant Walks 7000 Steps or More
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations ≥ the Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mortality and SOFA score increase at day 7
Endpoint domain: Mortality/survival
Primary endpoint: symptomatic hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: State Trait Anxiety Inventory (STAI) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number and type of treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: sera IgG4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Non presence of CSA-AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median Duration of Initial Dual Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Strict Changes in Initial Dual Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of hpATIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of [14C]-radioactivity excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fraction of [14C]-radioactivity excreted in faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurements of 5-HT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liebowitz Social Anxiety Scale (LSAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: catheterization success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dP/dt max response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BMI Z-score at 6-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BMI Z-score at 12-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decreased dietary fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increased self-reported leisure physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Correlation between MAP and ADR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Correlation between MAP and PDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Correlation between ADR and PDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ultrasonographic morphology of the endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants With Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Distance Corrected Intermediate Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of AZD1236 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with drug related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Goals Improved to Criterion
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of abnormal clinically significant vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of abnormal clinically significant ECG results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac adaptations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Haemoglobin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Subjective Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in evening PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of days without any drug administration at all
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of fully inhaled doses in relation to the total number of inhalations per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of missed doses per day as recommended
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of actually inhaled doses per day vs. the recommended number of inhalations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DMARD adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response Rate Of PGE2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of pathological specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of skin rash
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical findings in physical examination, vital signs and clinical laboratory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Buccal Peri-implant Mucosa Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated fetal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Level of Activated STAT1 (Phospho-STAT1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DTI changes in white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Events of Composite Morbidities and Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients reporting high/very high QoL changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Flu Vaccination Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Flu Vaccination Rate by Risk Level
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: High Confidence Flu Diagnosis Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid Volume Requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Postprandial appetite ratings changes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response Rate as Assessed by Number of Participants With Partial or Complete Response by Bladé Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity as Measured by Number of Participants Who Discontinued Treatment Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in WOMAC Pain Questionnaire Subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC Function Questionnaire Subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Global Assessment Subscore
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in Likert Scale Before and After Suctioning
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Responses to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Successful Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Flow in kidney and splanchnic vessels (mL/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perceived appetite
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in serum total antioxidative capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of areas for improvement in patient and families' journey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Major structural birth defects of newborns
Endpoint domain: Mortality/survival
Primary endpoint: Change in SUV max value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocyte human leukocyte antigen (mHLA-DR) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Epithelialisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vasopressors-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of bortezomib
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Prevalence of prefrailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In range - time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Cardiac function index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homeostasis model assessment-insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-167
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global longitudinal strain (TTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Deformation (CMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Haemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Decline of prostate specific antigen (PSA) of ≥20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quinnell classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Acute Febrile Illness (AFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 3D volumetric data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transplant Related Mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Relapse Free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: % of assigned days with confirmed use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Muscle twitch force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle voluntary activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate/Heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Borg's rate of perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Systemic Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes